| P2093 | author name string | Charles L Shapiro | |
| | William B Farrar | |
| | William E Carson | |
| | Barbara L Andersen | |
| | Lisa M Thornton | |
| P2860 | cites work | Taxanes for adjuvant treatment of early breast cancer | Q24242987 |
| | The CES-D Scale: A Self-Report Depression Scale for Research in the General Population | Q26778378 |
| | Phase II Trial of Taxol, an Active Drug in the Treatment of Metastatic Breast Cancer | Q33371932 |
| | Side-effects of chemotherapy and quality of life in ovarian and breast cancer patients | Q34496713 |
| | Depression, correlates of depression, and receipt of depression care among low-income women with breast or gynecologic cancer | Q34605151 |
| | Biobehavioral outcomes following psychological interventions for cancer patients | Q34713718 |
| | Distress reduction from a psychological intervention contributes to improved health for cancer patients | Q36087771 |
| | Psychological, behavioral, and immune changes after a psychological intervention: a clinical trial | Q36314628 |
| | Quality of life end points in cancer clinical trials: review and recommendations | Q38606655 |
| | Measuring the side effects of taxane therapy in oncology: the functional assesment of cancer therapy-taxane (FACT-taxane). | Q39391719 |
| | The importance of dose intensity in the outcome of chemotherapy | Q39514242 |
| | Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colo | Q40477055 |
| | Doxorubicin followed by sequential paclitaxel and cyclophosphamide versus concurrent paclitaxel and cyclophosphamide: 5-year results of a phase II randomized trial of adjuvant dose-dense chemotherapy for women with node-positive breast carcinoma | Q40591739 |
| | Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer | Q44902909 |
| | Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. | Q46493659 |
| | Adjuvant docetaxel for node-positive breast cancer | Q46522790 |
| | Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer | Q46658468 |
| | Postoperative dose-dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high-risk operable breast cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology Group | Q46691182 |
| | Breast cancer patients on adjuvant chemotherapy report a wide range of problems not identified by health-care staff. | Q53222910 |
| | Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer | Q72516643 |
| | Two shorter forms of the CES-D (Center for Epidemiological Studies Depression) depression symptoms index | Q74768419 |
| | Preventing paclitaxel-induced peripheral neuropathy: a phase II trial of vitamin E supplementation | Q80183756 |
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | chemotherapy | Q974135 |
| P304 | page(s) | 638-647 | |
| P577 | publication date | 2008-08-01 | |
| P1433 | published in | Cancer | Q326041 |
| P1476 | title | Delayed emotional recovery after taxane-based chemotherapy | |
| P478 | volume | 113 | |